StockDriftsStockDriftsTop 14 Davern Capital Partners LP Holdings
| Stock | Company | % Port. | Shares | Value | Activity | Ownership | Avg. Cost | Date |
|---|---|---|---|---|---|---|---|---|
| BNTX | BIONTECH SE | 11.97% | 754.5K | $70.2M | +147.35%(+449.50K) | $92.29(+0.70%) | 2026-06-30 | |
| ROIV | ROIVANT SCIENCES LTD | 11.66% | 1.93M | $68.4M | +121.31%(+1.06M) | $25.26(+43.63%) | 2026-06-30 | |
| RPRX | ROYALTY PHARMA PLC | 11.05% | 1.16M | $64.8M | +122.27%(+635.80K) | $44.80(+30.70%) | 2026-06-30 | |
| IONS | IONIS PHARMACEUTICALS INC | 10.8% | 798.7K | $63.3M | +106.44%(+411.81K) | $75.04(-25.55%) | 2026-06-30 | |
| INSM | INSMED INC | 10.18% | 559.8K | $59.7M | +206.65%(+377.26K) | $142.63(-11.43%) | 2026-06-30 | |
| REGN | REGENERON PHARMACEUTICALS | 9.85% | 92.6K | $57.8M | +106.79%(+47.84K) | $677.06(+19.04%) | 2026-06-30 | |
| LEGN | LEGEND BIOTECH CORP | 5.87% | 1.19M | $34.4M | -9.37%(-123.23K) | $25.75(-21.28%) | 2026-06-30 | |
| ALNY | ALNYLAM PHARMACEUTICALS INC | 5.8% | 113.1K | $34.0M | new | $308.56(-26.39%) | 2026-06-30 | |
| NTRA | NATERA INC | 5.51% | 119.0K | $32.3M | -17.36%(-24.99K) | $203.88(+52.43%) | 2026-06-30 | |
| GPCR | STRUCTURE THERAPEUTICS INC | 4.08% | 446.1K | $23.9M | +252.72%(+319.60K) | $51.66(+5.88%) | 2026-06-30 |
| Performance Metric | 3-Year Annualized | 3-Year Cumulative | 5-Year Annualized | 5-Year Cumulative | Since First Filing (2 quarters) |
|---|---|---|---|---|---|
| Top 20 Holdings Weighted | — | — | — | — | +10.02% |
| Top 20 Holdings Unweighted | — | — | — | — | +7.99% |
Davern Capital Partners LP reports $586.54M in US-listed equity holdings across 15 positions in its most recent 13F filing. Its largest disclosed positions are BNTX (12.0%), ROIV (11.7%) and RPRX (11.1%). The top 20 holdings account for 97.64% of reported assets. Its disclosed equity book has returned +10.02% cumulatively over 2 quarters. Figures reflect the Q2 2026 filing.
Portfolio changes
Every reported change this quarter, grouped by direction. The signal is in the rotation, not any single trade.
Sign up free to track Davern Capital Partners LP, compare funds side by side, and get alerts the moment positions change.
Holdings on this page are parsed from Davern Capital Partners LP’s Form 13F filings with the U.S. Securities and Exchange Commission (CIK 2003147). View Davern Capital Partners LP’s 13F filings on SEC